Mark G. Kris, MD, FASCO

Articles

Future Implications of ctDNA in the Management of NSCLC

July 7th 2022

A thoracic oncology expert provides perspective on ctDNA as a tool and its future as part of the NSCLC landscape.

Review of Recent Data on ctDNA From ASCO 2022

July 7th 2022

A comprehensive review of data presented at ASCO 2022 on ctDNA and MRD detection in NSCLC.

Two Key Uses for ctDNA in the Clinical Setting

July 7th 2022

Dr. Mark Kris shares insight on ctDNA and its use in detecting MRD in NSCLC.

Strategies for Monitoring Patients with NSCLC

July 7th 2022

Practical advice on monitoring options for patients with NSCLC treated with definitive radiation therapy or surgery.

Current Treatment Options for Patients with NSCLC

July 7th 2022

Mark G. Kris, MD, FASCO shares an overview of existing treatment options for patients with stage I-III non-small cell lung cancer.

Dr. Kris on Next Steps to Improve Outcomes in Lung Cancer

November 6th 2021

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the next steps to improve outcomes for patients with lung cancer.

Dr. Kris on Search for Biomarkers in Advanced Squamous NSCLC

November 13th 2019

Mark G. Kris, MD, discusses the ongoing search for additional biomarkers in advanced squamous non–small cell lung cancer.

Dr. Kris on the Impact of Bevacizumab Biosimilars in Lung Cancer

October 23rd 2019

Mark G. Kris, MD, discusses the impact biosimilars for bevacizumab (Avastin) could have in lung cancer.

Dr. Kris on the RELAY Trial in EGFR+ NSCLC

August 30th 2019

Mark G. Kris, MD, discusses the RELAY trial, which was an international, double-blind, randomized phase III study examining erlotinib in combination with ramucirumab versus placebo in previously untreated patients with EGFR-mutant metastatic non-small cell lung cancer.

Dr. Kris on Predicting Benefit With Osimertinib in EGFR+ NSCLC

June 13th 2019

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses methods for predicting benefit with osimertinib (Tagrisso) in patients with EGFR-positive non–small cell lung cancer (NSCLC).

Dr. Kris on Personalizing Therapy in Lung Cancer

March 20th 2019

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses personalizing therapy in the treatment of patients with lung cancer.

Dr. Kris Discusses Role of Antiangiogenesis in Lung Cancer

January 25th 2019

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the role of antiangiogenesis in the treatment of patients with lung cancer.

Dr. Kris on Adjuvant Systemic Therapy in NSCLC

November 10th 2018

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses adjuvant systemic therapy in patients with non–small cell lung cancer.

Dr. Kris on the FDA Approval of Dacomitinib in EGFR+ NSCLC

September 28th 2018

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of dacomitinib for the frontline treatment of patients with EGFR-positive locally advanced or metastatic non–small cell lung cancer.

Dr. Kris on Combination Chemotherapy Approaches in NSCLC

April 18th 2018

Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the use of chemotherapy in patients with non–small cell lung cancer (NSCLC).

Dr. Kris on the Future of Immunotherapy and Targeted Therapy in Lung Cancer

January 4th 2017

Mark G. Kris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses what the future holds for the development of immunotherapy and targeted therapy in the treatment of patients with lung cancer.

Dr. Kris on Sequencing Challenges in Lung Cancer

November 17th 2016

Mark G. Kris, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses challenges associated with sequencing in the treatment of patients with lung cancer.

Dr. Mark G. Kris on Side Effects Management with Immunotherapies

October 28th 2016

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses considerations for the management of immunotherapy toxicities.

Dr. Mark Kris on Immunotherapy and Frontline Options for Patients With NSCLC

June 18th 2016

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, explains what community oncologists need to know regarding immunotherapy and frontline treatment options for patients with non–small cell lung cancer (NSCLC).

Dr. Kris on the Challenges of Treating Lung Cancer

January 13th 2014

Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses some of the challenges of treating patients with lung cancer.